Orchestra BioMed Holdings, Inc. OBIO
6.05 USD +0.49 (+8.81%)
Nov 4, 2026, 1:18 PM EST
5.78 Day range 6.16
3.46 52-week range 6.50
- YTD
- +45.78%
- 1 year
- +61.76%
Financial health
Altman Z-Score
-2.93 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -3.7×
FY 2020 5y median -6.2× FY 2025
P/S 5.9×
FY 2020 5y median 55.8× FY 2025
P/B 3.1×
FY 2020 5y median 4.5× FY 2025
P/FCF -4.0×
FY 2020 5y median -6.6× FY 2025
EV/EBITDA -3.5×
FY 2020 5y median -5.6× FY 2025
EV/Sales 5.4×
FY 2020 5y median 53.7× FY 2025
FCF Yield -25.0%
FY 2020 5y median -15.2% FY 2025
Profitability
Gross Margin 99.4%
FY 2020 5y median 93.3% FY 2025
Operating Margin -154.7%
FY 2020 5y median -924.3% FY 2025
Net Margin -157.4%
FY 2020 5y median -951.3% FY 2025
ROE -83.2%
FY 2020 5y median -72.2% FY 2025
ROIC -52.4%
FY 2020 5y median -60.8% FY 2025
ROA -45.9%
FY 2020 5y median -51.6% FY 2025
Growth (YoY)
Revenue 1169.2%
FY 2020 FY 2025
Operating Income 19.4%
FY 2020 FY 2025
EPS (diluted) 33.1%
FY 2020 FY 2025
Free Cash Flow 2.7%
FY 2020 FY 2025
Financial Health
Current Ratio 6.4×
FY 2020 5y median 4.6× FY 2025
Quick Ratio 6.4×
FY 2020 5y median 4.5× FY 2025
Debt / Equity 0.3×
FY 2020 5y median 0.2× FY 2025
Net Debt / EBITDA 0.4×
FY 2020 5y median 0.2× FY 2025
Interest Coverage -45.1×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31